The maintenance of effect with tildrakizumab over 5 years is independent of baseline characteristics: pooled analysis of the phase 3 studies reSURFACE 1 and reSURFACE 2 in patients with moderate to severe psoriasis

被引：0
|
作者：
Thaci, Diamant [1 ]
Piaserico, Stefano [2 ]
Diemert, Sebastian [3 ]
Torres, Tiago [4 ]
机构：
[1] Univ Lubeck, Inst & Exzellenzzentrum Entzundungsmed, Lubeck, Germany
[2] Univ Padua, Dept Med, Unit Dermatol, Padua, Italy
[3] Almirall Hermal GmbH, Reinbek, Germany
[4] Ctr Hosp Univ Porto, Dept Dermatol, Porto, Portugal
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P071
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [1] Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, D.
    Jullien, D.
    Egeberg, A.
    Carrascosa, J. M.
    Wu, J. J.
    Pau-Charles, I.
    Gisondi, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : E709 - E711
  • [2] Efficacy of tildrakizumab in patients with moderate to severe psoriasis according to disease duration: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28
    Thaci, Diamant
    Iversen, Lars
    Pau-Charles, Ignasi
    Schoenenberger Lopez, Andreu
    Blauvelt, Andrew
    Puig, Lluis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB160 - AB160
  • [3] Tildrakizumab provides early predictability of response in patients with moderate to severe psoriasis: Results from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Warren, Richard B.
    Iversen, Lars
    Puig, Luis
    Fumero, Emilio
    Ryzhkova, Anna
    Schoenenberger Lopez, Andreu
    Feldman, Steven R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB10 - AB10
  • [4] Long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials
    van de Kerkhof, Peter C.
    Dauden, Esteban
    Pau-Charles, Ignasi
    Schoenenberger Lopez, Andreu
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB120 - AB120
  • [5] Efficacy responses with tildrakizumab in moderate-to-severe chronic plaque psoriasis patients with previous exposure to apremilast: Results of a pooled analysis of reSURFACE 1 and reSURFACE 2
    Gordon, Kenneth
    Reich, Kristian
    Pariser, David
    Menter, Alan
    Tyring, Stephen K.
    Sofen, Howard
    Rozzo, Stephen
    Parn, Jeffrey
    Li, Qing
    La Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB125 - AB125
  • [6] Long-term Safety of Tildrakizumab: Incidence of undesirable Events of particular Concern during the Treatment of Patients with moderate to severe Psoriasis in the reSURFACE 1 and reSURFACE 2 Studies over 5 Years
    Reich, K.
    Pinter, A.
    Kirsch, A.
    Pau-Charles, I
    Gerdes, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 57 - 58
  • [7] Stability of PASI <3 response to tildrakizumab through 5 years: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, Diamant
    Piaserico, Stefano
    Gaarn Du Jardin, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB113 - AB113
  • [8] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
    Elewski, Boni
    Han, George
    Rozzo, Stephen J.
    Gogineni, Ranga
    Schenkel, Brad
    Guenthner, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
  • [9] Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies
    Diamant Thaçi
    Sascha Gerdes
    Kristian Gaarn Du Jardin
    Jean-Luc Perrot
    Lluís Puig
    Dermatology and Therapy, 2022, 12 : 2325 - 2341
  • [10] Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies
    Thaci, Diamant
    Gerdes, Sascha
    Du Jardin, Kristian Gaarn
    Perrot, Jean-Luc
    Puig, Lluis
    DERMATOLOGY AND THERAPY, 2022, 12 (10) : 2325 - 2341
12345